RESULTS
RECRUITMENT
The trial began recruitment on 30 September 2021. On 10 June 2022, remdesivir enrollment was stopped as the prespecified success margin had been reached. Of the 439 patients screened by that time, 337 were randomized to either remdesivir (67 patients), no study drug (69 patients), or to other interventions (201 patients) [Consolidated Standards for Reporting Trials diagram of the PLATCOV phase 2 open-label, randomized, controlled adaptive platform trial for remdesivir in Thailand and Brazil. Enrollment ended 10 June 2022. Abbreviations: ATK, antigen test kit; BMI, body mass index; ECG, electrocardiogram; mITT, modified intention-to-treat; PCR, polymerase chain reaction.